Chemomab Therapeutics Ltd...

NASDAQ: CMMB · Real-Time Price · USD
0.94
0.04 (4.76%)
At close: Aug 15, 2025, 3:58 PM
0.95
1.58%
After-hours: Aug 15, 2025, 07:26 PM EDT

Chemomab Therapeutics Income Statement

Financials in USD. Fiscal year is January - December.
Fiscal Year Q1 2025 Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022 Q2 2022 Q1 2022 Q4 2021 Q3 2021 Q2 2021 Q1 2021
Period Ending Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021
Revenue
n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
Cost of Revenue
26.9K 26.9K 43.07K 62.01K 50.93K 9.1M 9.1M 17.4M 23.63M 14.6M 14.6M 6.29M 40.15K 34.04K 26.02K 20K 16K
Gross Profit
-26.9K -26.9K -43.07K -62.01K -50.93K -9.1M -9.1M -17.4M -23.63M -14.6M -14.6M -6.29M -40.15K -34.04K -22.99K -13.95K -6.93K
Operating Income
-14.18M -14.78M -15.46M -16.12M -20.55M -25.52M -30.27M -34.22M -32.28M -28.53M -24.91M -19.49M -15.99M -12.37M -9.29M -7.62M -5.97M
Interest Income
388.49K 570.49K 754.17K 984.42K 1.1M 1.24M 1.18M 1.18M 928.12K 830.55K 451.57K 216.47K 216.47K n/a 84.68K 91.73K 93.75K
Pretax Income
-13.4M -13.99M -14.48M -15.13M -19.35M -24.09M -28.87M -32.75M -31.56M -28.01M -24.81M -19.78M -15.9M -12.5M -9.42M -7.66M -5.96M
Net Income
-13.4M -13.99M -14.48M -15.06M -19.4M -24.25M -29.06M -33.31M -31.53M -27.88M -24.65M -19.3M -15.88M -12.48M -9.39M -7.65M -5.96M
Selling & General & Admin
3.51M 3.41M 3.36M 3.47M 5.81M 7.07M 9.07M 10.98M 11.14M 11.56M 11.45M 9.96M 8.07M 6.03M 4.08M 2.87M 1.68M
Research & Development
10.67M 11.32M 12.03M 12.54M 14.63M 18.37M 21.15M 23.23M 21.12M 16.98M 13.46M 9.53M 7.92M 6.33M 5.21M 4.75M 4.29M
Other Expenses
n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
Operating Expenses
14.18M 14.78M 15.45M 16.07M 20.5M 25.45M 30.22M 34.2M 32.26M 28.53M 24.91M 19.49M 15.99M 12.37M 9.29M 7.62M 5.97M
Interest Expense
n/a 2K 2K 2K 2K n/a 27K 264K 738.35K 738.35K 723.4K 563.76K 106.48K 111.43K 99.37K 22.01K 4.95K
Selling & Marketing Expenses
n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
Cost & Expenses
14.18M 14.78M 15.46M 16.1M 20.53M 25.49M 30.24M 34.2M 32.26M 28.53M 24.91M 19.49M 15.99M 12.37M 9.29M 7.62M 5.97M
Income Tax Expense
n/a -16.75K -16.75K -71.57K -37.57K 178.00 10.18K 302K -276K -297.03K -307.08K -544.12K -145.93 -45.45 4.55 46.68 72.48
Shares Outstanding (Basic)
22.81M 18.86M 17.53M 14.3M 14.21M 13.01M 11.82M 11.08M 11.05M 11.63M 11.44M 11.41M 11.4M 11.4M 11.4M 10.81M 7.84M
Shares Outstanding (Diluted)
22.81M 18.86M 17.53M 14.3M 14.21M 13.01M 11.82M 11.08M 11.05M 11.63M 11.44M 11.41M 11.4M 11.4M 11.4M 10.81M 7.84M
EPS (Basic)
-0.76 -0.89 -0.99 -1.14 -1.6 -2.2 -2.6 -2.8 -2.8 -2.4 -2.2 -1.68 -1.4 -1.18 -1.9 -3 -4.6
EPS (Diluted)
-0.76 -0.89 -0.99 -1.14 -1.6 -2.2 -2.6 -2.8 -2.8 -2.4 -2.2 -1.68 -1.4 -1.18 -1.9 -3 -4.6
EBITDA
-14.18M -14.74M -15.37M -16.03M -20.44M -25.43M -30.21M -34.14M -32.2M -28.48M -24.86M -19.44M -15.95M -12.33M -9.26M -7.59M -5.94M
EBIT
-14.18M -14.74M -15.37M -16.03M -20.46M -25.46M -30.25M -34.2M -32.26M -28.53M -24.91M -19.49M -15.99M -12.37M -9.29M -7.62M -5.97M
Depreciation & Amortization
60.25K 63.75K 63.17K 65.36K 67.68K 66.78K 64.57K 62.49K 60.51K 57.69K 54.78K 46.95K 40.15K 34.12K 29.07K 28.02K 26K